Wire · opportunities
Perioperative Enfortumab Vedotin Plus Pembrolizumab Does Not Compromise QOL in ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
The phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative treatment with enfortumab vedotin plus pembrolizumab did not significantly worsen quality of life compared to neoadjuvant gemcitabine and cisplatin in cisplatin-eligible muscle-invasive bladder cancer patients, while improving survival outcomes.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 1 source has reported it.
◆ ◆ The Wire takeaway
You can rely on enfortumab vedotin plus pembrolizumab as a perioperative option that preserves patient quality of life while improving survival in muscle-invasive bladder cancer. This opens a clearer path for biotech innovators to develop combined immunotherapies without sacrificing tolerability.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics